Efficacy and safety of minodronate in the treatment of glucocorticoid-induced osteoporosis

Efficacy and safety of minodronate in the treatment of glucocorticoid-induced osteoporosis - Effect of minodronate in glucocorticoid-induced osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011896

Enrollment

Registered

2013-09-27

Start date

2011-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lucocorticoid-induced osteoporosis

Interventions

Minodronate (1mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with rheumatic (connective tissue) diseases complicated with osteoporosis during the treatment with glucocorticoid

Exclusion criteria

Exclusion criteria: (1) Patients with peptic ulcers (2) Patients with esophageal stricture or achalasia (3) Patients unable to remain upright for 30 min after dosing 4) Patients with hypocalcaemia (5) Patients who received any prior bisphosphonate less than six months before entry (6) Females with pregnancy and lactating

Design outcomes

Primary

Measure	Time frame
(1) Changes in bone mineral density	—

Secondary

Measure	Time frame
(1) Changes in TRACP-5b, CTX, BAP, uNTX (2) Incident fracture	—

Countries

Japan

Contacts

Public ContactNoboru Kitamura

Department of Medicine, School of Medicine, Nihon University Division of Hematology and Rheumatology

noboruk@med.nihon-u.ac.jp03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026